ArticleCureus2025
Bone Marrow CD8+ Cytotoxic T-lymphocyte Subset: A Prognostic Indicator in Acute Myeloid Leukemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disorder with variable clinical outcomes due to the complex molecular and cytogenetic basis of the disease. In light of recent developments in immunotherapy, bone marrow (BM) microenvironment immune composition, including baseline lymphocyte subset profiles, may be relevant for understanding host-tumor immunologic interactions. We conducted a study on 88 newly diagnosed AML patients to evaluate the baseline BM CD8⁺/CD3⁺ cytotoxic T-lymphocyte (CTL) subset by flow cytometry and its relation to standard prognostic factors, response to induction therapy, and disease outcome. Our results showed that a higher percentage of BM CD8⁺/CD3⁺ CTLs (≥10%) was associated with significantly better overall survival (P = 0.020) and progression-free survival (P = 0.020) compared with cases with <10%. Moreover, a lower BM CD8⁺/CD3⁺ CTL percentage was associated with adverse prognostic parameters, including higher total leukocyte count (r = -0.512, P < 0.001) and higher blast counts in both BM (r = -0.290, P = 0.006) and peripheral blood (r = -0.364, P < 0.001). These findings suggest an important role of this subset in the antitumor immune response. Large-scale studies are warranted to confirm these results and further clarify the role of BM CTLs as a prognostic indicator and predictor of survival in AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.